Working with “living therapies” during COVID-19 has changed access, resource planning and management in CGT trials.
This ICON sponsored webinar program explores the bioethics of clinical trials at Preclinical and Phase 1 stages. An in-depth look at the unique nuances of cell and gene therapy (CGT) trials and how to keep them on track during COVID-19 will follow. The expert panel will conclude with a discussion on strategies for patient advocacy within this changed environment.
Register for the upcoming webinar to learn:
- What is the ethical protocol of approaching patients for early-stage clinical trials?
- What are the key differences between CGT clinical trials and traditional models?
- How has COVID-19 changed accessibility, resource planning and management of CGT trials?
- How has patient advocacy and support changed in the face of a global pandemic?
Global Business Lead, Cell and Gene Therapy, ICON
Steven Devine, MD, PhD
Chief Medical Officer, National Marrow Donor Program (NMDP)®/ Be The Match®
Patient Advocate and Founder, Raremark
Mark Yarborough, PhD
Dean’s Professor of Bioethics, University of California Davis
This webinar is sponsored by ICON in collaboration with the ISCT Market Access & Patient Advocacy (MAPA) Commercialization Subcommittee.